Nirogacestat Hydrobromide
FDA-approved product (tablet, oral), marketed as Ogsiveo.
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Gastrointestinal desmoid tumor
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antineoplastic agents
- FDA pharmacologic class
- Gamma Secretase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Nirogacestat Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- RegadenosonExisting use: Cardiovascular disease, Myocardial Perfusion Imaging48.4% AI-predicted activityagainst E. coli50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma48.2% AI-predicted activityagainst E. coliNo documented evidence found
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- ClozapineExisting use: Psychosis, Schizoaffective disorder, Schizophrenia48.1% AI-predicted activityagainst E. coli50+ registered studies
- FutibatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm48.0% AI-predicted activityagainst E. coli25 registered studies
- Atazanavir SulfateExisting use: HIV infection, HIV-1 infection, Infection and 1 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Daclatasvir DihydrochlorideExisting use: Chronic hepatitis C virus infection, Viral disease48.0% AI-predicted activityagainst E. coli2 registered studies
- AripiprazoleExisting use: Aggressive behavior, Agitation, Autism and 8 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Alclometasone DipropionateExisting use: Eye inflammation, Skin disease47.9% AI-predicted activityagainst E. coli2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
NCT04195399 · start 2020-10-07
Registered record
- Registry ID
- NCT04195399
- Conditions
- Desmoid Fibromatosis; Recurrent Desmoid Fibromatosis; Unresectable Desmoid Fibromatosis
- Interventions
- Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Nirogacestat Hydrobromide; Quality-of-Life Assessment; Questionnaire Administration; X-Ray Imaging
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-10-07
- Completion
- 2032-12-31
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDesmoid Fibromatosis; Recurrent Desmoid Fibromatosis; Unresectable Desmoid FibromatosisInterventionBiospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging +4 morePhasePhase 2Registry statusActive not recruiting